AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33992280 — intervention group
Group type: EXPERIMENTAL
Intervention: IASTM + conventional treatment
Number of subjects: 30
Study 33992280 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 30
Study 35378948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Huoxue method combined with platelet-rich plasma (PRP)
Number of subjects: 64
Study 35378948 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP) alone
Number of subjects: 64
Study 34535608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Riskometer™ app and informational leaflets
Number of subjects: 132
Study 34535608 — intervention group
Group type: COMPARATOR
Intervention: Standard management including information leaflets only
Number of subjects: 132
Study 34535608 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke Riskometer™ app
Number of subjects: 132
Study 36036379 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Non-Dominant Lower Limb Training (UNDLT)
Number of subjects: 39
Study 36036379 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Dominant Lower Limb Training (UDLT)
Number of subjects: 39
Study 36036379 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 34970214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency repetitive transcranial magnetic stimulation (rTMS) at 10 Hz for 7 consecutive days
Number of subjects: 60
Study 34970214 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 35468660 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ED (n=30)
Number of subjects: 60
Study 35468660 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study 33873029 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NMRT/F
Number of subjects: 768
Study 33873029 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NMRF/F
Number of subjects: 768
Study 33873029 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NMRT/T
Number of subjects: 768
Study 33873029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine clearance
Number of subjects: 768
Study 33873029 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlling for cotinine glucuronidation
Number of subjects: 768
Study 36339187 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based continuum of care intervention model including management teams, health knowledge delivery, health intervention records, supervision, home visiting, and psychological guidance.
Number of subjects: 80
Study 36339187 — intervention group
Group type: COMPARATOR
Intervention: Routine distribution of health education materials and health education through health-themed lectures.
Number of subjects: 80
Study 33793027 — intervention group
Group type: EXPERIMENTAL
Intervention: E + MOD + RS + horizontal zirconia post (ZP)
Number of subjects: 64
Study 33793027 — intervention group
Group type: EXPERIMENTAL
Intervention: E + MOD + RS
Number of subjects: 64
Study 33793027 — intervention group
Group type: EXPERIMENTAL
Intervention: E + MOD
Number of subjects: 64
Study 33793027 — intervention group
Group type: COMPARATOR
Intervention: Sound single-rooted
Number of subjects: 64
Study 33793027 — intervention group
Group type: COMPARATOR
Intervention: Sound double-rooted
Number of subjects: 64
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HER2 blockade arm
Number of subjects: 80
Study 32034581 — intervention group
Group type: COMPARATOR
Intervention: Single blockade arm
Number of subjects: 80
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB after NAT
Number of subjects: 80
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB
Number of subjects: 80
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB with 1 SLN detected
Number of subjects: 80
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB with 2 SLNs detected
Number of subjects: 80
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB with more than 2 SLNs detected
Number of subjects: 80
Study 32034581 — intervention group
Group type: EXPERIMENTAL
Intervention: SLNB with more than 1 SLN and clipped nodes removed simultaneously
Number of subjects: 80
Study 35975719 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 60
Study 35975719 — intervention group
Group type: COMPARATOR
Intervention: Autologous Blood Injection (ABI)
Number of subjects: 60
Study 33112273 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid thermal ablation
Number of subjects: 450
Study 33112273 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy
Number of subjects: 450
Study 35605163 — intervention group
Group type: EXPERIMENTAL
Intervention: C3RT intervention
Number of subjects: 146
Study 35605163 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 146
Study 33581683 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise
Number of subjects: 60
Study 33581683 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 60
Study 33581683 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise
Number of subjects: 60
Study 32601710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS) - 20 bilateral treatments (1 session per day, 5 days per week over a 4-week period)
Number of subjects: 8
Study 32601710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 8
Study 35058263 — intervention group
Group type: EXPERIMENTAL
Intervention: True somatic acupressure (SA) intervention for 7 weeks
Number of subjects: 51
Study 35058263 — intervention group
Group type: COMPARATOR
Intervention: Sham somatic acupressure (light acupressure at non-acupoints)
Number of subjects: 51
Study 35058263 — intervention group
Group type: COMPARATOR
Intervention: Usual care (education booklet regarding FSD symptom cluster management)
Number of subjects: 51
Study 34496450 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic supplementation (800 mg/day)
Number of subjects: 80
Study 34496450 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 80
Study 36307830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention app (mHealth tool addressing logistical and motivational barriers)
Number of subjects: 0
Study 36307830 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention app (mHealth tool)
Number of subjects: 0
Study 36307830 — intervention group
Group type: COMPARATOR
Intervention: Control app (providing general pediatric health information)
Number of subjects: 0
Study 34151413 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg QD for 5 days
Number of subjects: 20
Study 34151413 — intervention group
Group type: EXPERIMENTAL
Intervention: Islatravir 2.25 mg QD for 14 days
Number of subjects: 20
Study 34151413 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of islatravir 2.25 mg and doravirine 100 mg QD for 5 days
Number of subjects: 20
Study 34151413 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD for 5 days
Number of subjects: 20
Study 34151413 — intervention group
Group type: COMPARATOR
Intervention: Placebo QD for 14 days
Number of subjects: 20
Study 32063509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitching distance of 18.44 m
Number of subjects: 26
Study 32063509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitching distance of 19.05 m
Number of subjects: 26
Study 32063509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitching distance of 19.41 m
Number of subjects: 26
Study 32063509 — intervention group
Group type: EXPERIMENTAL
Intervention: All pitching distances (18.44 m, 19.05 m, 19.41 m)
Number of subjects: 26
Study 35716442 — intervention group
Group type: EXPERIMENTAL
Intervention: WriteForIBD (4-day, 30-min writing program adapted for IBD)
Number of subjects: 19
Study 35716442 — intervention group
Group type: COMPARATOR
Intervention: Active control (writing about trivial topics)
Number of subjects: 19
Study 33283731 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine combined with low-dose CEG regimen (DCEG)
Number of subjects: 45
Study 33283731 — intervention group
Group type: COMPARATOR
Intervention: Decitabine combined with low-dose CAG regimen (DCAG)
Number of subjects: 45
Study 33283731 — intervention group
Group type: COMPARATOR
Intervention: Decitabine combined with low-dose CEG regimen (DCEG) and Decitabine combined with low-dose CAG regimen (DCAG)
Number of subjects: 45
Study 33706000 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 242
Study 33706000 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 242
Study 33706000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (GSV length ablated ≥34 cm)
Number of subjects: 242
Study 33706000 — intervention group
Group type: COMPARATOR
Intervention: Group II (GSV length ablated <34 cm)
Number of subjects: 242
Study 33706000 — intervention group
Group type: COMPARATOR
Intervention: GSV diameter <5.5 mm
Number of subjects: 242
Study 33706000 — intervention group
Group type: EXPERIMENTAL
Intervention: GSV diameter ≥5.5 mm
Number of subjects: 242
Study 33706000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 242
Study 33272223 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 477
Study 33272223 — intervention group
Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 477
Study 33883816 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable meloxicam (n = 136)
Number of subjects: 271
Study 33883816 — intervention group
Group type: COMPARATOR
Intervention: Control (saline; n = 135)
Number of subjects: 271
Study 32940569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Number of subjects: 8
Study 32940569 — intervention group
Group type: COMPARATOR
Intervention: Conventional Radiotherapy (CR)
Number of subjects: 8
Study 34261600 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghamz therapy
Number of subjects: 80
Study 34261600 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 80
Study 36376852 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraglottic jet oxygenation and ventilation (SJOV)
Number of subjects: 72
Study 36376852 — intervention group
Group type: COMPARATOR
Intervention: Nasal cannula
Number of subjects: 72
Study 33852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelato APF Gel
Number of subjects: 96
Study 33852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Remin Pro
Number of subjects: 96
Study 33852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse
Number of subjects: 96
Study 33852758 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Number of subjects: 96
Study 33852758 — intervention group
Group type: EXPERIMENTAL
Intervention: Curodont Protect
Number of subjects: 96
Study 33852758 — intervention group
Group type: COMPARATOR
Intervention: Control group (no remineralization)
Number of subjects: 96
Study 36449768 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcontrast T1 vibe images
Number of subjects: 194
Study 36449768 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 fast spin echo
Number of subjects: 194
Study 36449768 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontrast T1 vibe
Number of subjects: 194
Study 36449768 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 turbo inversion recovery magnitude sequence
Number of subjects: 194
Study 36449768 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection capability ratios
Number of subjects: 194
Study 33236169 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving Simulator tasks at BAC level 0.05%
Number of subjects: 46
Study 33236169 — intervention group
Group type: COMPARATOR
Intervention: Driving Simulator tasks at BAC level 0
Number of subjects: 46
Study 33236169 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving Simulator tasks at BAC levels 0.025% and 0.09%
Number of subjects: 46
Study 35567549 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter promotion of articles
Number of subjects: 694
Study 35567549 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no active tweeting)
Number of subjects: 694
Study 32641236 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 400
Study 32641236 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 400
Study 36054481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Delivery with Enhanced Stop Light Diet (RD/eSLD)
Number of subjects: 92
Study 36054481 — intervention group
Group type: COMPARATOR
Intervention: Remote Delivery with Conventional Diet (RD/CD)
Number of subjects: 92
Study 36054481 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face with Conventional Diet (FTF/CD)
Number of subjects: 92
Study 34227958 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 430
Study 34227958 — intervention group
Group type: COMPARATOR
Intervention: Non-hypertensive group
Number of subjects: 430
Study 32271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 0
Study 32271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) with concomitant valproate
Number of subjects: 0
Study 32271618 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) with concomitant clobazam
Number of subjects: 0
Study 34717013 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot retraining group (BAR)
Number of subjects: 103
Study 34717013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadence retraining group (CAD)
Number of subjects: 103
Study 34717013 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 103
Study 33284677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d of vitamin D3
Number of subjects: 688
Study 33284677 — intervention group
Group type: COMPARATOR
Intervention: 200 IU/d of vitamin D3 (control)
Number of subjects: 688
Study 33284677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3
Number of subjects: 688
Study 33284677 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d of vitamin D3
Number of subjects: 688
Study 33284677 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU/d or higher doses of vitamin D3
Number of subjects: 688
Study 33284677 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-with-best-dose group (1000 IU/d)
Number of subjects: 688
Study 32135126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg followed by misoprostol 200 mcg buccally
Number of subjects: 176
Study 32135126 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by misoprostol 200 mcg buccally
Number of subjects: 176
Study 35763247 — intervention group
Group type: COMPARATOR
Intervention: Upacicalcet (0.025 to 0.8 mg single-dose)
Number of subjects: 18
Study 35763247 — intervention group
Group type: COMPARATOR
Intervention: Upacicalcet (0.05 to 0.2 mg multiple-dose)
Number of subjects: 18
Study 35763247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33413428 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 30
Study 33413428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34378365 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 24
Study 34378365 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bevacizumab
Number of subjects: 24
Study 34378365 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab (in homologous recombination deficiency positive tumors)
Number of subjects: 24
Study 35333783 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted albumin infusions
Number of subjects: 143
Study 35333783 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 143
Study 32307430 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin (intravenously, drip 20.0 ml in 250.0 ml 5% glucose for 14 days)
Number of subjects: 100
Study 32307430 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 100
Study 36297076 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory meal consumed two hours post-exercise
Number of subjects: 56
Study 36297076 — intervention group
Group type: COMPARATOR
Intervention: Pro-inflammatory meal consumed two hours post-exercise
Number of subjects: 56
Study 34015532 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance score (<0.5) for predicting phenotypic susceptibility
Number of subjects: 204
Study 34015532 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance score (≥1) for predicting resistance
Number of subjects: 204
Study 35258771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 58
Study 32991818 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 66
Study 36226798 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reminder app
Number of subjects: 275
Study 36226798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study 33819329 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (n = 48)
Number of subjects: 19
Study 33819329 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic acellular dermal matrix (n = 68)
Number of subjects: 19
Study 33819329 — intervention group
Group type: COMPARATOR
Intervention: Comparison between xenogeneic and allogeneic groups
Number of subjects: 19
Study 35730363 — intervention group
Group type: EXPERIMENTAL
Intervention: Panel management intervention using PrEP Coordinators and a web-based panel management tool
Number of subjects: 10
Study 34346168 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg astegolimab every 4 weeks
Number of subjects: 502
Study 34346168 — intervention group
Group type: EXPERIMENTAL
Intervention: 210 mg astegolimab every 4 weeks
Number of subjects: 502
Study 34346168 — intervention group
Group type: EXPERIMENTAL
Intervention: 490 mg astegolimab every 4 weeks
Number of subjects: 502
Study 34346168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 36126073 — intervention group
Group type: EXPERIMENTAL
Intervention: Arca Aerosolized Hydrogen Peroxide Decontamination System with 3% H2O2 for 45 minutes
Number of subjects: 8
Study 36126073 — intervention group
Group type: COMPARATOR
Intervention: Control: 3% H2O2 for 120 minutes
Number of subjects: 8
Study 36126073 — intervention group
Group type: COMPARATOR
Intervention: Control: 12% H2O2 for 120 minutes
Number of subjects: 8
Study 36126073 — intervention group
Group type: COMPARATOR
Intervention: Positive control: Not exposed to H2O2
Number of subjects: 8
Study 33438713 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable methods
Number of subjects: 1012
Study 33438713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation-based methods
Number of subjects: 1012
Study 33438713 — intervention group
Group type: COMPARATOR
Intervention: Coexpression-based methods
Number of subjects: 1012
Study 33438713 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable and mediation-based methods
Number of subjects: 1012
Study 33736675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (0.82 mg/m2/week in group A to 0.65 mg/m2/week in group D)
Number of subjects: 1062
Study 33736675 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Number of subjects: 1062
Study 32652581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor perceptions of program practices (setting expectations, prematch mentor training, matching based on mentor preferences)
Number of subjects: 537
Study 32652581 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor commitment
Number of subjects: 537
Study 32652581 — intervention group
Group type: EXPERIMENTAL
Intervention: Program practices (setting clear expectations, amount of prematch training, matching by preferences)
Number of subjects: 537
Study 34694189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-based physiotherapy
Number of subjects: 14
Study 33444970 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond consumption (2 servings, 56 g/day)
Number of subjects: 69
Study 33444970 — intervention group
Group type: COMPARATOR
Intervention: Biscuit snack (isocaloric, high carbohydrate)
Number of subjects: 69
Study 33422409 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFMEDS intervention with usual teaching
Number of subjects: 42
Study 33422409 — intervention group
Group type: COMPARATOR
Intervention: Usual teaching only (Control)
Number of subjects: 42
Study 33422409 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFMEDS intervention with usual teaching (Fluency Achieved)
Number of subjects: 42
Study 33422409 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFMEDS intervention with usual teaching (Fluency Not Achieved)
Number of subjects: 42
Study 36495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ulipristal acetate regimens
Number of subjects: 135
Study 36495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-body mass index (BMI) women
Number of subjects: 135
Study 36495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population analysis
Number of subjects: 135
Study 33568086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (CI) in children aged 4-6 years
Number of subjects: 38
Study 33568086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (CI) in children aged 7-9 years
Number of subjects: 38
Study 33568086 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing peers (control group)
Number of subjects: 38
Study 35869569 — intervention group
Group type: EXPERIMENTAL
Intervention: Montessori-Based Nutrition Program
Number of subjects: 51
Study 33573687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle choice and coaching intervention
Number of subjects: 388
Study 33573687 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 388
Study 34637450 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention, median 6 sessions out of 8, delivered remotely.
Number of subjects: 96
Study 34637450 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) intervention.
Number of subjects: 96